[HTML][HTML] Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
[HTML][HTML] Comorbidities, multimorbidity and COVID-19
The influence of comorbidities on COVID-19 outcomes has been recognized since the
earliest days of the pandemic. But establishing causality and determining underlying …
earliest days of the pandemic. But establishing causality and determining underlying …
[HTML][HTML] The T cell immune response against SARS-CoV-2
P Moss - Nature immunology, 2022 - nature.com
The adaptive immune response is a major determinant of the clinical outcome after SARS-
CoV-2 infection and underpins vaccine efficacy. T cell responses develop early and …
CoV-2 infection and underpins vaccine efficacy. T cell responses develop early and …
[HTML][HTML] A guide to immunotherapy for COVID-19
FL van de Veerdonk, E Giamarellos-Bourboulis… - Nature medicine, 2022 - nature.com
Immune dysregulation is an important component of the pathophysiology of COVID-19. A
large body of literature has reported the effect of immune-based therapies in patients with …
large body of literature has reported the effect of immune-based therapies in patients with …
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo …
Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-
inflammatory properties. This study evaluates the efficacy and safety of baricitinib in …
inflammatory properties. This study evaluates the efficacy and safety of baricitinib in …
[HTML][HTML] Innate immune evasion strategies of SARS-CoV-2
JM Minkoff, B tenOever - Nature Reviews Microbiology, 2023 - nature.com
Abstract SARS-CoV-2, the virus responsible for the COVID-19 pandemic, has been
associated with substantial global morbidity and mortality. Despite a tropism that is largely …
associated with substantial global morbidity and mortality. Despite a tropism that is largely …
[HTML][HTML] Current and novel biomarkers of thrombotic risk in COVID-19: a consensus statement from the international COVID-19 thrombosis biomarkers colloquium
Abstract Coronavirus disease 2019 (COVID-19) predisposes patients to thrombotic and
thromboembolic events, owing to excessive inflammation, endothelial cell activation and …
thromboembolic events, owing to excessive inflammation, endothelial cell activation and …
[HTML][HTML] Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 …
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
Effect of noninvasive respiratory strategies on intubation or mortality among patients with acute hypoxemic respiratory failure and COVID-19: the RECOVERY-RS …
Importance Continuous positive airway pressure (CPAP) and high-flow nasal oxygen
(HFNO) have been recommended for acute hypoxemic respiratory failure in patients with …
(HFNO) have been recommended for acute hypoxemic respiratory failure in patients with …
[HTML][HTML] Pathophysiology of COVID-19-associated acute kidney injury
Although respiratory failure and hypoxaemia are the main manifestations of COVID-19,
kidney involvement is also common. Available evidence supports a number of potential …
kidney involvement is also common. Available evidence supports a number of potential …